Joint degeneration is one of the most common sources of chronic pain and disability worldwide. Whether it affects the knee, hip, shoulder, or ankle, the process follows a similar pattern: gradual loss of articular cartilage, changes in the underlying bone, synovial inflammation, and progressive loss of joint function. For many patients, conventional management provides symptom relief but does not address the underlying deterioration.
This regenerative approach is an emerging approach that uses the regenerative properties of mesenchymal stem cells (MSCs) to reduce inflammation, support cartilage homeostasis, and potentially slow the progression of joint breakdown.
What Causes Joint Degeneration
Articular cartilage covers the ends of bones in joints, providing a smooth, low-friction surface for movement. Unlike most tissues, cartilage has a very limited capacity for self-repair – it contains no blood vessels and has a low cell density relative to its volume. Once damaged, cartilage does not regenerate effectively on its own.
Joint degeneration treatment has traditionally focused on managing the symptoms of this process:
- NSAIDs and analgesics for pain
- Corticosteroid injections to reduce inflammation
- Hyaluronic acid injections to support lubrication
- Physical therapy to maintain joint mobility and muscle support
- Eventually, joint replacement surgery in advanced cases
These approaches can meaningfully improve quality of life, but they do not halt or reverse the underlying degenerative process. This is the gap that regenerative medicine seeks to address.
How MSC-Based Stem Cell Therapy Works for Joints
Mesenchymal stem cells have multiple properties that make them relevant to joint degeneration treatment:
Immunomodulation: MSCs release paracrine factors – including anti-inflammatory cytokines such as IL-10 and TGF-β – that can shift the inflammatory environment of a degenerated joint from destructive to more regenerative.
Trophic support: MSCs support the survival and function of chondrocytes (cartilage cells) by releasing growth factors that promote cell survival and matrix production.
Potential cartilage support: In some contexts, MSCs may differentiate toward a chondrocyte-like phenotype, contributing to cartilage tissue repair, though the dominant mechanism in vivo appears to be paracrine rather than direct cell replacement.
Anti-fibrotic effects: MSCs may help reduce the fibrotic changes in joint tissue that accompany chronic degeneration.
As described in the foundational work by Caplan and Correa, MSCs function as a kind of biological “injury drugstore” – responding to local damage signals by releasing a suite of bioactive molecules tailored to the injury environment (Caplan & Correa, Cell Stem Cell, 2011).
What the Clinical Evidence Shows
The evidence base for intra-articular MSC injection in joint degeneration has grown substantially over the past decade.
An early clinical pilot study involving six patients with knee osteoarthritis who received intra-articular injections of autologous bone marrow-derived MSCs showed improvements in pain and function, with evidence of cartilage changes on imaging in some participants, supporting the feasibility of this approach (Emadedin et al., Arch Iran Med., 2012).
A Phase I/II randomized controlled trial compared two doses of autologous bone marrow MSC injections against hyaluronic acid alone in patients with knee osteoarthritis. Both MSC doses produced greater improvement in pain and functional outcomes compared to hyaluronic acid at 12 months, and the higher dose group showed evidence of cartilage quality changes on MRI (Lamo-Espinosa et al., J Transl Med., 2016).
A Phase I dose-escalation study using adipose tissue-derived MSCs for severe knee osteoarthritis found the treatment to be safe and well-tolerated across dose groups, with evidence of clinical improvement in pain and joint function, supporting the safety profile of this approach (Pers et al., Stem Cells Transl Med. 2016).
Recovery Tips After Stem Cell Joint Therapy
Recovery from intra-articular MSC injection requires thoughtful activity management to allow the regenerative process to take hold without being disrupted by excessive mechanical loading.
Weeks 1–2: Minimize high-impact activities. Walking on flat surfaces is generally acceptable, but avoid running, jumping, heavy lifting, or deep squatting.
Weeks 3–6: Gradually reintroduce low-impact exercise such as cycling or swimming. Continue avoiding heavy loading of the treated joint.
Months 2–3: Most patients begin to notice meaningful improvement in pain and function during this period. Physical therapy focused on joint stability and muscle balance is beneficial.
Months 3–6: Full activity can typically resume, guided by symptoms and clinical assessment. Some patients continue to show gradual improvement over 6–12 months.
Lifestyle factors also influence outcomes: maintaining a healthy weight reduces mechanical load on the joint, adequate sleep supports recovery, and avoiding smoking improves the biological environment for tissue repair.
Frequently Asked Questions
How long does it take to see results from MSC-based joint treatment?
Most patients begin to notice improvement between 6 and 12 weeks after injection, with continued improvement over 3–6 months. The regenerative process works gradually, and results should not be evaluated too early.
Are stem cell joint injections a permanent solution?
Outcomes vary. Some patients experience durable improvement over several years; others may benefit from periodic retreatment. The goal is to meaningfully reduce pain, improve function, and potentially slow the progression of degeneration.
Which joints can be treated with stem cell therapy?
MSC-based injection therapy has been studied most extensively for the knee, but the approach is applied to other joints including the hip, shoulder, and ankle. The evidence base varies by joint, with the knee having the most clinical data.
Is stem cell joint therapy covered by insurance?
Currently, MSC-based joint injection therapy is generally considered investigational and is not covered by most standard insurance plans. Costs vary by provider and protocol.
Key Takeaways
- Intra-articular MSC therapy uses MSCs to modulate inflammation, support cartilage health, and potentially slow joint deterioration
- Clinical trials show improvements in pain, function, and in some cases cartilage MRI findings with intra-articular MSC injection
- Recovery requires graded return to activity over 6–12 weeks, with full activity by 3 months in most patients
- Adipose-derived and bone marrow-derived MSCs are both used, with a favorable safety profile across dose-escalation studies
- Outcomes are influenced by severity of degeneration, patient age, weight, and adherence to recovery guidance
- A thorough evaluation including current imaging helps determine candidacy
To learn more about stem cell therapy at Ways2Well, book a stem cell therapy consultation or schedule a consultation with our medical team to discuss whether this approach is right for your joint health.
References
- Caplan AI, Correa D. “The MSC: An injury drugstore.” Cell Stem Cell. 2011;9(1):11–15. DOI: https://doi.org/10.1016/j.stem.2011.06.008
- Emadedin M, Aghdami N, Taghiyar L, et al. “Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis.” Arch Iran Med. 2012;15(7):422–428. PMID: 22724878. https://pubmed.ncbi.nlm.nih.gov/22724878/
- Lamo-Espinosa JM, Mora G, Blanco JF, et al. “Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II).” J Transl Med. 2016;14(1):246. DOI: https://doi.org/10.1186/s12967-016-0998-2
- Pers YM, Rackwitz L, Ferreira R, et al. “Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial.” Stem Cells Transl Med. 2016;5(7):847–856. DOI: https://doi.org/10.5966/sctm.2015-0245
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member